NUTRIVENTION-4

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

What will happen during the trial?

The purpose of this study is to compare maintenance therapy approaches in people with newly diagnosed multiple myeloma (MM) that has responded well to a first round of treatment. The researchers will compare giving the usual maintenance therapy (lenalidomide) with giving daratumumab as maintenance therapy, and they will look at which drug gives participants a better health-related quality of life during treatment. The researchers will measure participants' quality of life using various questionnaires. This study will help researchers find out whether this different approach of giving daratumumab as maintenance therapy is better, the same as, or worse than the usual approach.

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
100 patients (estimated)
Sponsors
Memorial Sloan Kettering Cancer Center
Collaborators
Janssen Research & Development LLC
Tags
Monoclonal Antibody, CD38, Maintenance
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1134
NCT Identifier
NCT04497961

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.